Literature DB >> 22984225

Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility.

Ryan T Bushey1, Philip Lazarus.   

Abstract

UDP-glucuronosyltransferase (UGT) 2A1 is a respiratory and aerodigestive tract-expressing phase II detoxifying enzyme that metabolizes various xenobiotics including polycyclic aromatic hydrocarbons (PAHs). In the present study, a novel exon 3 deletion splice variant was identified for UGT2A1 (UGT2A1Δexon3). As determined by reverse transcription-polymerase chain reaction (PCR), UGT2A1Δexon3 was shown to be expressed in various tissues including lung, trachea, larynx, tonsil, and colon. The ratio of UGT2A1Δexon3/wild-type UGT2A1 expression was highest in colon (0.79 ± 0.08) and lung (0.42 ± 0.12) as determined by real-time PCR; an antibody specific to UGT2A1 showed splice variant protein (UGT2A1_i2) to wild-type protein (UGT2A1_i1) ratios in the range of 0.5 to 0.9 in these tissues. Using ultra-pressure liquid chromatography, we found that homogenates prepared from UGT2A1_i2-overexpressing human embryonic kidney 293 cells exhibited no glucuronidation activity against PAHs, including benzo[a]pyrene-7,8-dihydrodiol (B[a]P-7,8-diol). An inducible in vitro system was created to determine the effect of UGT2A1_i2 expression on UGT2A1_i1 activity. Increasing UGT2A1_i2 levels resulted in a significant (p < 0.01) decrease in the UGT2A1_i1 V(max) against 1-hydroxy (OH)-pyrene, 3-OH-benzo[a]pyrene, and B[a]P-7,8-diol; no significant changes in K(M) were observed for any of the three substrates. Coimmunoprecipitation experiments suggested the formation of UGT2A1_i1 and UGT2A1_i2 hetero-oligomers and UGT2A1_i1 homo-oligomers; coexpression of UGT2A1_i1 or UGT2A1_i2 with other UGT1A or UGT2B enzymes caused no change in UGT1A or UGT2B glucuronidation activity. These data suggest that a novel UGT2A1 splice variant regulates UGT2A1-mediated glucuronidation activity via UGT2A1-specific protein-protein interactions, and expression of this variant could play an important role in the detoxification of carcinogens within target tissues for tobacco carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22984225      PMCID: PMC3500542          DOI: 10.1124/jpet.112.198770

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

1.  Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactions.

Authors:  Judith Bellemare; Mélanie Rouleau; Mario Harvey; Chantal Guillemette
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

2.  A molecular model of the human UDP-glucuronosyltransferase 1A1, its membrane orientation, and the interactions between different parts of the enzyme.

Authors:  Liisa Laakkonen; Moshe Finel
Journal:  Mol Pharmacol       Date:  2010-03-09       Impact factor: 4.436

3.  Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis.

Authors:  Ryan T Bushey; Gang Chen; Andrea S Blevins-Primeau; Jacek Krzeminski; Shantu Amin; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-02       Impact factor: 2.089

4.  Extensive splicing of transcripts encoding the bile acid-conjugating enzyme UGT2B4 modulates glucuronidation.

Authors:  Eric Lévesque; Vincent Ménard; Isabelle Laverdière; Judith Bellemare; Olivier Barbier; Hugo Girard; Chantal Guillemette
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

5.  UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility.

Authors:  Rene M Balliet; Gang Chen; Ryan W Dellinger; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

6.  Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction.

Authors:  Michael H Court; Suwagmani Hazarika; Soundararajan Krishnaswamy; Moshe Finel; J Andrew Williams
Journal:  Mol Pharmacol       Date:  2008-06-03       Impact factor: 4.436

7.  Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

Authors:  Renee M Balliet; Gang Chen; Carla J Gallagher; Ryan W Dellinger; Dongxiao Sun; Philip Lazarus
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

8.  Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene.

Authors:  Kristine C Olson; Ryan W Dellinger; Qing Zhong; Dongxiao Sun; Shantu Amin; Thomas E Spratt; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2009-07-09       Impact factor: 3.922

9.  The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases.

Authors:  Katriina Itäaho; Peter I Mackenzie; Shin-ichi Ikushiro; John O Miners; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2008-08-21       Impact factor: 3.922

10.  UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly.

Authors:  Taina Sten; Ingo Bichlmaier; Tiia Kuuranne; Antti Leinonen; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

View more
  9 in total

1.  Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Authors:  Douglas F Dluzen; Dongxiao Sun; Anna C Salzberg; Nate Jones; Ryan T Bushey; Gavin P Robertson; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2014-01-07       Impact factor: 4.030

2.  Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues.

Authors:  A Tourancheau; M Rouleau; S Guauque-Olarte; L Villeneuve; I Gilbert; A Droit; C Guillemette
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

3.  Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing.

Authors:  Adrien Labriet; Eric P Allain; Michèle Rouleau; Yannick Audet-Delage; Lyne Villeneuve; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2018-02-09       Impact factor: 3.922

4.  Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing.

Authors:  A Tourancheau; G Margaillan; M Rouleau; I Gilbert; L Villeneuve; E Lévesque; A Droit; C Guillemette
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

5.  Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism.

Authors:  Ryan T Bushey; Douglas F Dluzen; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2012-10-18       Impact factor: 3.922

6.  Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics.

Authors:  Michèle Rouleau; Yannick Audet-Delage; Sylvie Desjardins; Mélanie Rouleau; Camille Girard-Bock; Chantal Guillemette
Journal:  Front Pharmacol       Date:  2017-02-03       Impact factor: 5.810

7.  Regulation of UGT2A1 by miR-196a-5p and miR-196b-5p.

Authors:  Aimee K Sutliff; Christy J W Watson; Gang Chen; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2019-03-08       Impact factor: 4.030

8.  Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.

Authors:  Delores J Grant; Ani Manichaikul; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Lauren C Peres; Edward S Peters; Ann G Schwartz; Paul D Terry; Xin-Qun Wang; Temitope O Keku; Cathrine Hoyo; Andrew Berchuck; Dale P Sandler; Jack A Taylor; Katie M O'Brien; Digna R Velez Edwards; Todd L Edwards; Alicia Beeghly-Fadiel; Nicolas Wentzensen; Celeste Leigh Pearce; Anna H Wu; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Joseph H Rothstein; Francesmary Modugno; Roberta Ness; Kirsten Moysich; Mary Anne Rossing; Jennifer A Doherty; Thomas A Sellers; Jennifer B Permuth-Way; Alvaro N Monteiro; Douglas A Levine; Veronica Wendy Setiawan; Christopher A Haiman; Loic LeMarchand; Lynne R Wilkens; Beth Y Karlan; Usha Menon; Susan Ramus; Simon Gayther; Aleksandra Gentry-Maharaj; Kathryn L Terry; Daniel W Cramer; Ellen L Goode; Melissa C Larson; Scott H Kaufmann; Rikki Cannioto; Kunle Odunsi; John L Etter; Ruea-Yea Huang; Marcus Q Bernardini; Alicia A Tone; Taymaa May; Marc T Goodman; Pamela J Thompson; Michael E Carney; Shelley S Tworoger; Elizabeth M Poole; Diether Lambrechts; Ignace Vergote; Adriaan Vanderstichele; Els Van Nieuwenhuysen; Hoda Anton-Culver; Argyrios Ziogas; James D Brenton; Line Bjorge; Helga B Salvensen; Lambertus A Kiemeney; Leon F A G Massuger; Tanja Pejovic; Amanda Bruegl; Melissa Moffitt; Linda Cook; Nhu D Le; Angela Brooks-Wilson; Linda E Kelemen; Paul D P Pharoah; Honglin Song; Ian Campbell; Diana Eccles; Anna DeFazio; Catherine J Kennedy; Joellen M Schildkraut
Journal:  Cancer Med       Date:  2019-04-18       Impact factor: 4.711

9.  The odorant metabolizing enzyme UGT2A1: Immunolocalization and impact of the modulation of its activity on the olfactory response.

Authors:  Fabrice Neiers; David Jarriault; Franck Menetrier; Loïc Briand; Jean-Marie Heydel
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.